Get started
Author

J.A.D.M. De Roos

Observed names: J A Roos, J. Roos, J.A.D.M. de Roos, Juliane Roos
ORCID: 0009-0001-2697-0772
Observed ORCID: 0009-0001-2697-0772
OpenAlex ID: A5112014089
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
2015 · A.R.R. Maia, J. de Man, et al. · Annals of Oncology · 129
RETRACTED: Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis
2010 · A. J. M. Schuerwegh, A. Ioan-Facsinay, et al. · Proceedings of the National Academy of Sciences · 97
Corridor disease in South Africa: a review of the current status.
1988 · F T Potgieter, W H Stoltsz, et al. · PubMed · 38
The use of a single complement fixation test technique in bovine brucellosis, Johne's disease, dourine, equine piroplasmosis and Q fever serology.
1985 · S Herr, H F Huchzermeyer, et al. · PubMed · 34
PDF
The isolation of Theileria? Taurotragi in South Africa.
1981 · A J De Vos, J A Roos · PubMed · 21
PDF
Observations on the transmission of Theileria mutans in South Africa.
1981 · A J De Vos, J A Roos · PubMed · 13
PDF
Chemotherapy of Theileria parva lawrencei infections in cattle with halofuginone.
1983 · A J De Vos, J A Roos · PubMed · 9
PDF
Self-Reported Baseline Quality of Life Mirrors Treatment-Specific Characteristics of Cancer Patients
2023 · Anja Thronicke, Shiao Li Oei, et al. · Cancers · 5
PDF
Lymph node pathology in Trypanosoma brucei-infected sheep.
1979 · P R Barrowman, J A Roos · PubMed · 4
PDF
Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW)
2025 · Anja Thronicke, Patricia Grabowski, et al. · International Journal of Molecular Sciences · 2
PDF
Translation and Cultural Adaptation of the MYCaW® Questionnaire into German: The iSWOP Study Protocol
2025 · Anja Thronicke, Lisa Schille, et al. · medRxiv · 1
A Matching‐adjusted Indirect Comparison of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2023 · P. Ghia, A. Skarbnik, et al. · Hematological Oncology · 1
PDF
Cell panel profiling of pre-clinical and clinical anti-cancer agents reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
2016 · J.C.M. Uitdehaag, J.A.D.M. De Roos, et al. · European Journal of Cancer · 1
Symptoms in Cancer of the Pancreas
1979 · A.J. Limburg, J. Roos · Journal of the Royal College of Physicians of London · 1
Translation and Cultural Adaptation of the Measure Yourself Concerns and Wellbeing (MYCaW) Questionnaire Into German: Protocol for the iSWOP Study
2025 · Anja Thronicke, Lisa Schille, et al. · JMIR Research Protocols
PDF
PO-456 Cell line panel profiling of all clinically approved kinase inhibitors for cancer treatment
2018 · J.J. Kooijman, J.C.M. Uitdehaag, et al. · ESMO Open
PO-484 Development of a two-step screening-and-confirmation approach to efficiently identify synergistic drug combinations with the PARP inhibitor niraparib
2018 · M.B.W. Prinsen, J.R.F. De Vetter, et al. · ESMO Open
Mechanistic differentiation of PI3K/mTOR, Aurora kinase and EZH2 inhibitor classes by comparative cancer cell line profiling
2016 · J.C.M. Uitdehaag, J.A.D.M. De Roos, et al. · European Journal of Cancer
349 Synergistic drug combinations that target beta-catenin-driven and MYC-driven cancers
2014 · J.C.M. Uitdehaag, J.A.P. Spijkers-Hagelstein, et al. · European Journal of Cancer
655: Identification of new synergistic drug combinations on basis of cell panel profiling
2014 · J.C.M. Uitdehaag, J.A.D.M. De Roos, et al. · European Journal of Cancer
Works count: 20
Citation count: 356
H-index: 7
I10-index: 6
Year
Topic
Type